Page 2 - Orchid Pharma

After 7,700% surge in stock, Orchid Pharma to face reality check

New owners have to divest part of their stake of about 98 per cent in the firm, which re-listed in Mumbai in early November after emerging from bankruptcy

Orchid Pharma rises from ashes, expects to make profits in 12 months

Dhanuka Pharmaceuticals that took over the company almost a year ago, nursed it back to health from bankruptcy

This pharma stock has zoomed over 10,000% in 96 trading days

Orchid Pharma shares were locked in the upper circuit for the 96th straight trading day

This pharma stock has zoomed 567% in 40 trading days post re-listing

According to latest shareholding pattern data, the company's promoter held 98.04 per cent stake

Orchid Pharma approves amalgamation of Dhanuka Pharma with itself

Issues 10,000 equity shares of OPL for Rs 10 each at par to the shareholders of DPPL

Dhanuka Lab implements resolution plan for debt-ridden Orchid Pharma

The resolution plan will fetch the secured lenders around 32.3% recovery

SC sets aside NCLAT order on Dhanuka's resolution plan for Orchid Pharma

The apex court's ruling effectively gives the green signal to Dhanuka's plan for Orchid Pharma

NCLT dissolves Orchid Pharma's promoter firm, says no gain for shareholders

CoC says parent firm has no assets other than holding in Orchid Pharma, which itself is undergoing CIRP; Even if there is a resolution for Orchid Pharma, nothing would be left for investors

SC orders interim stay on NCLAT order on Orchid Pharma resolution process

SBI filed the appeal with the Supreme Court to set aside the NCLAT order alleging that the appellate tribunal erred in overriding the commercial wisdom of the CoC

NCLAT sets aside Dhanuka's resolution plan for debt-laden Orchid Pharma

NCLT had approved Dhanuka's resolution plan on June 25, 2019

NCLAT stays NCLT order approving Dhanuka Lab's resolution plan for Orchid

The CoC had selected the proposal of Dhanuka Laboratories and gone ahead with the voting even as Accord Life Spec approached the NCLT against CoC's decision

NCLT approves okays Dhanuka Laboratories' resolution plan for Orchid Pharma

Creditors to get Rs 1,116 crore, which is lower than liquidation value

Financial creditors of Orchid Pharma likely to see larger haircut

A total of 24 financial creditors have an accepted claim of around Rs 3,390 crore from Orchid Pharma

Ready to revise resolution plan for Orchid Pharma: Accord to NCLT

Chennai-based Accord Life Spec Pvt Ltd on Wednesday told the tribunal that it was ready to revise its proposal to Rs 615 crore

Dhanuka Lab bid for Orchid Pharma hits new wall as one lender changes vote

Punjab National Bank (International) Limited dissents minutes before e-voting closes, taking the assents to below the 66% threshold

Dhanuka Lab bid for Orchid Pharma hits new wall as one lender changes vote

Punjab National Bank (International) Limited dissents minutes before e-voting closes, taking the assents to below the 66% threshold

Three pharma firms in second race for Orchid Pharma resolution process

Sources say Dhanuka Laboratories has an edge over the other two, Chennai-based Accord Life Spec and Covalent Labs

Orchid Pharma Ltd sees net loss narrowing to Rs 13.44 crore in Q4

The company has been under Corporate Insolvency Resolution Process (CIRP) and the Resolution Professional has received three resolution plans from prospective bidders

Orchid Pharma says closer to resolution as RP has received three plans

NCLT had earlier cancelled the resolution plan by US-based Ingen Capital after it refused to infuse the upfront amount, seeking certain data from the drug maker.

NCLAT rules against Ingen for delaying Orchid Pharma resolution plan

An NCLAT bench comprising Justice S J Mukhopadhaya and Justice Bansi Lal Bhat directed the Centre through the Ministry of Corporate Affairs to take appropriate steps